Cargando…
Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series
Vesicovaginal fistula (VVF) is the nonphysiological communication between the bladder and vagina, and surgical closure is the gold treatment standard. Despite that successful closure occurs in around 85% of patients after the first repair, recurrence remains a highly distressing complication for pat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947156/ https://www.ncbi.nlm.nih.gov/pubmed/31810344 http://dx.doi.org/10.3390/jcm8122122 |
_version_ | 1783485484170739712 |
---|---|
author | Streit-Ciećkiewicz, Dominika Futyma, Konrad Miotła, Paweł Grzybowska, Magdalena Emilia Rechberger, Tomasz |
author_facet | Streit-Ciećkiewicz, Dominika Futyma, Konrad Miotła, Paweł Grzybowska, Magdalena Emilia Rechberger, Tomasz |
author_sort | Streit-Ciećkiewicz, Dominika |
collection | PubMed |
description | Vesicovaginal fistula (VVF) is the nonphysiological communication between the bladder and vagina, and surgical closure is the gold treatment standard. Despite that successful closure occurs in around 85% of patients after the first repair, recurrence remains a highly distressing complication for patients and surgeons. The aim of our study was to evaluate the efficacy of a platelet-rich plasma (PRP) injection as a supportive treatment in the surgical repair of recurrent VVF. Between January 2018 and July 2019, 16 patients with recurrent VVF were injected with PRP in a tertiary gynecological department. Subsequently, a surgical Latzko procedure for VVF closure was scheduled 6–8 weeks after the PRP injection allowing proper neovascularization and remodeling of surrounding tissues. Patients were considered cured if no leakage was observed after surgery and negative dye test results were indicated at follow-up. All patients who were examined therein remained dry. To the best of our knowledge, this is the first study aiming to assess PRP injections as a supporting treatment prior to surgical procedure for recurrent VVF. Preliminary results are encouraging, and we incorporated this method in our clinical practice. Further reports on a larger group will follow. |
format | Online Article Text |
id | pubmed-6947156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69471562020-01-13 Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series Streit-Ciećkiewicz, Dominika Futyma, Konrad Miotła, Paweł Grzybowska, Magdalena Emilia Rechberger, Tomasz J Clin Med Article Vesicovaginal fistula (VVF) is the nonphysiological communication between the bladder and vagina, and surgical closure is the gold treatment standard. Despite that successful closure occurs in around 85% of patients after the first repair, recurrence remains a highly distressing complication for patients and surgeons. The aim of our study was to evaluate the efficacy of a platelet-rich plasma (PRP) injection as a supportive treatment in the surgical repair of recurrent VVF. Between January 2018 and July 2019, 16 patients with recurrent VVF were injected with PRP in a tertiary gynecological department. Subsequently, a surgical Latzko procedure for VVF closure was scheduled 6–8 weeks after the PRP injection allowing proper neovascularization and remodeling of surrounding tissues. Patients were considered cured if no leakage was observed after surgery and negative dye test results were indicated at follow-up. All patients who were examined therein remained dry. To the best of our knowledge, this is the first study aiming to assess PRP injections as a supporting treatment prior to surgical procedure for recurrent VVF. Preliminary results are encouraging, and we incorporated this method in our clinical practice. Further reports on a larger group will follow. MDPI 2019-12-02 /pmc/articles/PMC6947156/ /pubmed/31810344 http://dx.doi.org/10.3390/jcm8122122 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Streit-Ciećkiewicz, Dominika Futyma, Konrad Miotła, Paweł Grzybowska, Magdalena Emilia Rechberger, Tomasz Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series |
title | Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series |
title_full | Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series |
title_fullStr | Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series |
title_full_unstemmed | Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series |
title_short | Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series |
title_sort | platelet-rich plasma as adjuvant therapy for recurrent vesicovaginal fistula: a prospective case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947156/ https://www.ncbi.nlm.nih.gov/pubmed/31810344 http://dx.doi.org/10.3390/jcm8122122 |
work_keys_str_mv | AT streitcieckiewiczdominika plateletrichplasmaasadjuvanttherapyforrecurrentvesicovaginalfistulaaprospectivecaseseries AT futymakonrad plateletrichplasmaasadjuvanttherapyforrecurrentvesicovaginalfistulaaprospectivecaseseries AT miotłapaweł plateletrichplasmaasadjuvanttherapyforrecurrentvesicovaginalfistulaaprospectivecaseseries AT grzybowskamagdalenaemilia plateletrichplasmaasadjuvanttherapyforrecurrentvesicovaginalfistulaaprospectivecaseseries AT rechbergertomasz plateletrichplasmaasadjuvanttherapyforrecurrentvesicovaginalfistulaaprospectivecaseseries |